Taken together, these findings indicate that combination therapy with a PI3K–AKT–mTOR pathway inhibitor in patients with advanced prostate cancer may overcome the cytoprotective effects of PARP inhibitor-induced AKT activation, perhaps with additional benefit in those with PTEN deficiency and increased AKT signaling. Here, PIK3CB is linked to prostate carcinoma.